Outlook Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
OTLK Nasdaq 2836 www.outlooktherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Outlook Therapeutics, Inc.

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event - Jun 18th, 2025 7:05 am
Outlook’s wet AMD treatment accepted by SMC for NHS Scotland - Jun 11th, 2025 3:06 am
Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - Jun 10th, 2025 6:05 am
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD - Jun 2nd, 2025 5:00 am
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering - May 23rd, 2025 4:30 am
Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants - May 22nd, 2025 2:01 pm
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update - May 15th, 2025 2:01 pm
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - Apr 8th, 2025 6:45 am
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration - Feb 28th, 2025 6:05 am
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - Feb 19th, 2025 7:00 am
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - Feb 14th, 2025 6:05 am
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment - Feb 4th, 2025 7:05 am
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors - Jan 31st, 2025 6:05 am
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD - Jan 23rd, 2025 7:05 am
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - Jan 22nd, 2025 7:05 am
Sector Update: Health Care Stocks Rise Late Afternoon - Jan 16th, 2025 1:54 pm
Outlook Therapeutics Shares Fall After Reporting Trial Results for ONS-5010 in Wet AMD - Jan 16th, 2025 10:44 am
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug - Jan 16th, 2025 10:09 am
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial - Jan 16th, 2025 4:00 am
Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss - Dec 30th, 2024 5:45 am